177 related articles for article (PubMed ID: 26553421)
1. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.
Bernabeu I; Pico A; Venegas E; Aller J; Alvarez-Escolá C; García-Arnés JA; Marazuela M; Jonsson P; Mir N; García Vargas M;
Pituitary; 2016 Apr; 19(2):127-37. PubMed ID: 26553421
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
3. ACROSTUDY: the Italian experience.
Grottoli S; Maffei P; Bogazzi F; Cannavò S; Colao A; Ghigo E; Gomez R; Graziano E; Monterubbianesi M; Jonsson P; De Marinis L
Endocrine; 2015 Feb; 48(1):334-41. PubMed ID: 25150035
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
5. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
7. ACROSTUDY: Status Update on 469 Patients.
Brue T
Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
[TBL] [Abstract][Full Text] [Related]
8. ACROSTUDY: the first 5 years.
Trainer PJ
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S19-24. PubMed ID: 19684052
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
[TBL] [Abstract][Full Text] [Related]
10. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
[TBL] [Abstract][Full Text] [Related]
11. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
[TBL] [Abstract][Full Text] [Related]
12. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
[TBL] [Abstract][Full Text] [Related]
13. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Fleseriu M; Führer-Sakel D; van der Lely AJ; De Marinis L; Brue T; van der Lans-Bussemaker J; Hey-Hadavi J; Camacho-Hubner C; Wajnrajch MP; Valluri SR; Palladino AA; Gomez R; Salvatori R
Eur J Endocrinol; 2021 Aug; 185(4):525-538. PubMed ID: 34342594
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY.
Buchfelder M; van der Lely AJ; Biller BMK; Webb SM; Brue T; Strasburger CJ; Ghigo E; Camacho-Hubner C; Pan K; Lavenberg J; Jönsson P; Hey-Hadavi JH
Eur J Endocrinol; 2018 Dec; 179(6):419-427. PubMed ID: 30325178
[TBL] [Abstract][Full Text] [Related]
17. Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY.
Grottoli S; Bianchi A; Bogazzi F; Bona C; Carlsson MO; Colao A; Dassie F; Giampietro A; Gomez R; Granato S; Maffei P; Pivonello R; Prencipe N; Ragonese M; Urbani C; Cannavò S
J Endocrinol Invest; 2022 Aug; 45(8):1535-1545. PubMed ID: 35359232
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy in acromegaly patients treated with pegvisomant.
van der Lely AJ; Gomez R; Heissler JF; Åkerblad AC; Jönsson P; Camacho-Hübner C; Kołtowska-Häggström M
Endocrine; 2015 Aug; 49(3):769-73. PubMed ID: 25542184
[TBL] [Abstract][Full Text] [Related]
19. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients).
Barraud S; Caron P; Raingeard I; Lefebvre H; Raverot G; Cortet-Rudelli C; Desailloud R; Henocque R; Brault Y; Brue T; Chanson P; Delemer B
Ann Endocrinol (Paris); 2021 Dec; 82(6):582-589. PubMed ID: 34256010
[TBL] [Abstract][Full Text] [Related]
20. Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY.
van der Lely AJ; Jönsson P; Wilton P; Åkerblad AC; Cara J; Ghigo E
Eur J Endocrinol; 2016 Oct; 175(4):239-45. PubMed ID: 27401863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
